MYCMI-6 has GI50s as low as 0.5 μM in neuroblastoma and Burkitt’s lymphoma cells with deregulated MYCN/MYC, which is much more potent in comparison to most of the previously reported MYC:MAX inhibitors, such as 10058-F4, 10058-F4 analogues and 10074-G5. The gene discussed is MYCN; the disease is neuroblastoma.